BRISTOL-MYERS SQUIBB CO

How Bristol‑Myers Squibb’s no‑charge Eliquis Medicaid deal boosts brand equity, drives U.S. market share, and may set a new pricing precedent for high‑cost drugs.

Bank of America upgrades Bristol‑Myers Squibb to “Buy,” citing a robust, diversified oncology‑and‑cardiovascular pipeline that could offset patent risks and boost investor optimism.

Explore Bristol‑Myers Squibb’s latest analyst upgrades, dividend growth, and AI‑driven pipeline prospects – a balanced view of risk, reward, and ESG‑friendly strategy for investors.

Bristol-Myers Squibb’s share price has rallied due to expectations of continued revenue growth from its oncology and immunology pipeline, driven by proactive market-access initiatives and a balanced mix of high-margin and high-risk projects.

Bristol-Myers Squibb’s $1.5 billion acquisition of Orbital Therapeutics positions the company to capitalize on the growing market for RNA-mediated cell therapies, potentially generating $5-8 billion in incremental revenue over the next decade.

Bristol-Myers Squibb Co. has reported positive clinical and reimbursement developments, including encouraging data from a late-stage clinical study and a favorable reimbursement recommendation for its OPDIVO subcutaneous formulation in Quebec, which…

Bristol-Myers Squibb’s stock price has declined by 25% over the past decade, but the biopharmaceutical industry is expected to grow due to increasing demand for innovative treatments, including those for uveal melanoma and cancer.

Bristol-Myers Squibb Co has received Breakthrough Therapy Designation from the FDA for its lung cancer treatment, izalontamab brengitecan, a significant milestone in the development of innovative cancer therapies.

Bristol-Myers Squibb’s CAR T cell therapy, Breyanzi, has secured FDA priority review in marginal zone lymphoma, a move that is expected to boost investor confidence and solidify the company’s position in the market.

Bristol-Myers Squibb has reported a strong second-quarter earnings performance, exceeding expectations with a 4.1% revenue increase and 36.4% rise in adjusted earnings per share.